HepatoPac® Highlights - Volume 7, March, 2014

HepatoPac™ Highlights

In this Newsletter:

Join us at SOT 2014

Society of Toxicology ToxExpo
Phoenix, Arizona
March 23-27, 2014

BOOTH #1471

Sponsored Symposium:
Title: The Use of Human HepatoPac®, an In Vitro Microliver Platform, for Predictive Toxicology Presenter: Edward LeCluyse, The Hamner Institute 3/25/2014 | 1:30PM - 2:30PM | Room 101A West

Podium Presentation:
Title: Engineering the Microscale Environment Around iPSC-Derived Human Hepatocytes In Vitro Presenter: Salman Khetani, University of Colorado 3/24/2014 | 9:20AM | North Ballroom 120B


  • Modified High-content Imaging Micropatterned Hepatocyte Co-Culture Model for Predictive Toxicology Abstract #1973, Poster #245
  • Evaluation of the Toxicity Profiles of Selected Bioactivated Compounds in Primary Rat Hepatocytes Cultured in Micropatterned Co-cultures Abstract #1042, Poster #524
  • Comparative Metabolism of Eight Model Pharmaceutical Compounds in Rat- and Human- Liver Microsomes, Suspension Hepatocytes, and Micropatterned Co-cultures of Primary Hepatocytes Abstract #1895, Poster #267

Upcoming Webinar

Application of HepatoPac® Toward Developing an Integrated Understanding of the Disposition and Metabolism of Faldaprevir.
Presented by: Diane Ramsden, Boehringer-Ingelheim Pharmaceuticals, Inc.

4/9/2014 | 11AM - 12PM

Learn More

Topics covered include:

  • Application of human HepatoPac® to delineate the importance of transporter and enzyme interplay
  • Insights into the formation, disposition and elimination of faldaprevir to provide an integrated model of faldaprevir clearance
  • Validation of the human HepatoPac® model using rat HepatoPac® to provide an IVIVC

Webinar Associated Peer-Reviewed Publications

  • Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac™.   Ramsden, D et al. Drug Metab Dispos March 2014 42:384-39. Read More
  • Generating an IVIVC for metabolism and liver enrichment of an HCV drug, faldaprevir, using a rat hepatocyte model (HepatoPac™).   Ramsden, D et al. Drug Metab Dispos March 2014 42:384-393. Read More
  • Enzyme-Transporter Interplay in the Formation and Clearance of Abundant Metabolites of Faldaprevir Found in Excreta but not in Circulation. Li, Y et al. Drug Metab Dispos March 2014 42:384-393. Read More


Mid-Atlantic User Group Meeting

Annual User Group MTG

May 21, 2014
8:30AM - 4:00PM
Philadelphia Marriott West
Philadelphia, PA


The Hepregen Mid-Atlantic User Group Meeting will bring together users and prospective users of Hepregen's HepatoPac™ micro-liver platform to discuss practical applications in the fields of drug metabolism and toxicology. Registration is free, but space is limited.

Attendees Will Learn:

  • About innovative new HepatoPac applications
  • How scientists are using HepatoPac in practical situations
  • About the latest validation data
  • About recent developments and new pre-clinical species models

Confirmed Speakers:

Edward LeCluyse; The Hamner Institutes
Mary Grubb; Bristol-Meyers Squibb
Okey Ukairo; Hepregen Corporation

Learn More

Whats New

Human Metabolic Stability Kit



Human Metabolic Stability Kit
Primary hepatocytes in HepatoPac® co-cultures remain metabolically active for up to 35 days allowing for highly accurate metabolic stability studies specializing in slowly metabolized compounds.

Kits Contain:

  • Human HepatoPac® Co-Cultures
  • Maintenance Media
  • Application-specific Media and additives
  • Instructions for culture maintenance and application-specific protocols

Bring the predictive power of the HepatoPac® micro-liver platform to your lab with these ready-to-use kits.

Request a Quote